126 related articles for article (PubMed ID: 30564618)
1. Several household chemical exposures are associated with pediatric-onset multiple sclerosis.
Mar S; Liang S; Waltz M; Casper TC; Goyal M; Greenberg B; Weinstock-Guttman B; Rodriguez M; Aaen G; Belman A; Barcellos LF; Rose J; Gorman M; Benson L; Candee M; Chitnis T; Harris Y; Kahn I; Roalsted S; Hart J; Lotze T; Moodley M; Ness J; Rensel M; Rubin J; Schreiner T; Tillema JM; Waldman A; Krupp L; Graves JS; Waubant E;
Ann Clin Transl Neurol; 2018 Dec; 5(12):1513-1521. PubMed ID: 30564618
[TBL] [Abstract][Full Text] [Related]
2. Logistic regression analysis of risk factors for pediatric burns: a case-control study in underdeveloped minority areas in China.
Lin Z; Iyappan P; Huang Z; Sooranna SR; Wu Y; Lan L; Huang C; Liang F; Zhao D; Huang D
Front Pediatr; 2024; 12():1365492. PubMed ID: 38655278
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study.
Nørgaard M; Veres K; Didden EM; Wormser D; Magyari M
Mult Scler Relat Disord; 2019 Feb; 28():81-85. PubMed ID: 30576846
[TBL] [Abstract][Full Text] [Related]
4. Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study.
Song J; Westerlind H; McKay KA; Almqvist C; Stridh P; Kockum I; Hillert J; Manouchehrinia A
J Neurol; 2019 Feb; 266(2):481-486. PubMed ID: 30578428
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
6. The neural basis of fatigue in multiple sclerosis: A multimodal MRI approach.
Novo AM; Batista S; Alves C; d'Almeida OC; Marques IB; Macário C; Santana I; Sousa L; Castelo-Branco M; Cunha L
Neurol Clin Pract; 2018 Dec; 8(6):492-500. PubMed ID: 30588379
[TBL] [Abstract][Full Text] [Related]
7. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.
Gasperini C; Prosperini L; Tintoré M; Sormani MP; Filippi M; Rio J; Palace J; Rocca MA; Ciccarelli O; Barkhof F; Sastre-Garriga J; Vrenken H; Frederiksen JL; Yousry TA; Enzinger C; Rovira A; Kappos L; Pozzilli C; Montalban X; De Stefano N;
Neurology; 2019 Jan; 92(4):180-192. PubMed ID: 30587516
[TBL] [Abstract][Full Text] [Related]
8. Repurposing of omeprazole for oligodendrocyte differentiation and remyelination.
Zhu K; Sun J; Kang Z; Zou Z; Wu X; Wang Y; Wu G; Harris RA; Wang J
Brain Res; 2019 May; 1710():33-42. PubMed ID: 30590025
[TBL] [Abstract][Full Text] [Related]
9. 'It's the unknown' - understanding anxiety: from the perspective of people with multiple sclerosis.
Butler E; Thomas R; Carolan A; Silber E; Chalder T
Psychol Health; 2019 Mar; 34(3):368-383. PubMed ID: 30588838
[TBL] [Abstract][Full Text] [Related]
10. Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Neurol; 2018; 9():1071. PubMed ID: 30581413
[TBL] [Abstract][Full Text] [Related]
11. Neurological update: MOG antibody disease.
Wynford-Thomas R; Jacob A; Tomassini V
J Neurol; 2019 May; 266(5):1280-1286. PubMed ID: 30569382
[TBL] [Abstract][Full Text] [Related]
12. Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis.
Ben-Zacharia A; Adamson M; Boyd A; Hardeman P; Smrtka J; Walker B; Walker T
Int J MS Care; 2018; 20(6):287-297. PubMed ID: 30568566
[TBL] [Abstract][Full Text] [Related]
13. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
[TBL] [Abstract][Full Text] [Related]
14. Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Satchidanand N; Drake A; Smerbeck A; Hojnacki D; Kolb C; Patrick K; Weinstock-Guttman B; Motl R; Benedict RH
Mult Scler; 2020 Jan; 26(1):91-98. PubMed ID: 30566030
[TBL] [Abstract][Full Text] [Related]
15. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
Arreola-Mora C; Silva-Pereyra J; Fernández T; Paredes-Cruz M; Bertado-Cortés B; Grijalva I
Mult Scler Relat Disord; 2019 Feb; 28():117-124. PubMed ID: 30593980
[TBL] [Abstract][Full Text] [Related]
16. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies for Multiple Sclerosis: An Update.
Graf J; Aktas O; Rejdak K; Hartung HP
BioDrugs; 2019 Feb; 33(1):61-78. PubMed ID: 30604390
[TBL] [Abstract][Full Text] [Related]
18. Predicting clinical progression in multiple sclerosis after 6 and 12 years.
Dekker I; Eijlers AJC; Popescu V; Balk LJ; Vrenken H; Wattjes MP; Uitdehaag BMJ; Killestein J; Geurts JJG; Barkhof F; Schoonheim MM
Eur J Neurol; 2019 Jun; 26(6):893-902. PubMed ID: 30629788
[TBL] [Abstract][Full Text] [Related]
19. Diet and Multiple Sclerosis: Scoping Review of Web-Based Recommendations.
Beckett JM; Bird ML; Pittaway JK; Ahuja KD
Interact J Med Res; 2019 Jan; 8(1):e10050. PubMed ID: 30626570
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases.
Herden L; Weissert R
Front Nutr; 2018; 5():133. PubMed ID: 30622948
[No Abstract] [Full Text] [Related]
[Next] [New Search]
